08/29/2026
Oscity BioSciences’ Role — Proprietary, Patented Cannabinoid Solutions
Understanding the endocannabinoid system is only the beginning. The real opportunity lies in developing cannabinoid-based products that can work with it more effectively and deliver meaningful therapeutic value.
Oscity BioSciences is focused on exactly that. We are advancing proprietary, patented technologies centered on cannabinoid cocrystals, including our L-proline covered by U.S. patents 11,168,047 and 11,993,563. These innovations address key limitations of traditional forms: improved solid-state properties, enhanced purity pathways, greater stability, and the potential for better formulation and delivery characteristics needed for pharmaceutical and advanced therapeutic applications.
Our platform is designed to support the development of high-purity isolates and specialized formulas (including those aimed at inflammatory, , and related conditions) that can more reliably engage the body’s own endocannabinoid system. In our cGMP-certified facility, we are building toward scalable manufacturing and rigorous regulatory pathways so that these proprietary compounds can move from science into real-world therapeutic value.
The is fundamental. BioSciences is committed to developing the next generation of tools that work with it.
www.oscity.com
*D *Dcocrystals
Oscity Biosciences — patented co-crystal cannabinoid technology, pharmaceutical-grade API wholesale, and exclusive licensing from Foley, Alabama.